等待开盘 07-01 09:30:00 美东时间
0.000
0.00%
Plus Therapeutics (PSTV) shares rose in early premarket trading after its subsidiary CNSide Diagnostics announced an agreement with Elevance Health (ELV) to expand coverage for a cancer screening test...
06-25 20:02
Plus Therapeutics will host a business update conference call on June 30, 2026, at 8:30 a.m. ET, discussing progress on its CNS cancer diagnostics, lead drug Reyobiq, and integrated AI plans. CEO Marc H. Hedrick highlights advancements in diagnostics, therapeutics, and AI, aiming to improve outcomes for CNS oncology patients and deliver long-term value to shareholders. The call will also cover the CNSide diagnostic launch and the company's vision...
06-23 11:30
Top analysts changed their views on top stocks. For all changes, upgrades and downgrades, see analyst ratings page.
06-08 21:52
U.S. RESEARCH ROUNDUP- Adobe, Allstate, Teleflex June 8 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Adobe, Allstate and Teleflex on Monday. HIGHLIGHTS * Adobe Inc ADBE.O : TD Cowen cuts target price to $285 from $310
06-08 16:01
An announcement from Plus Therapeutics ( ($PSTV) ) is now available. On June 1,...
06-06 06:26
CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a healthcare company advancing precision diagnostics and radiopharmaceuticals for central nervous
06-04 19:32
Plus Therapeutics, Inc. (Nasdaq: PSTV) ("Plus" or the "Company"), a healthcare company developing and commercializing precision diagnostics and radiopharmaceuticals for central nervous system (CNS) cancers, today
05-26 19:35
Partnership to deliver a novel AI-native integrated CNS oncology platformPlatform will unify and analyze Plus' proprietary therapeutic, diagnostic, and bioinformatics datasets to accelerate precision
05-19 19:34
Plus Therapeutics ( ($PSTV) ) has shared an update. Plus Therapeutics, Inc. hel...
05-16 06:50
Plus Therapeutics (NASDAQ:PSTV) reported quarterly losses of $(1.05) per share which missed the analyst consensus estimate of $(0.85) by 23.53 percent. This is a 96.48 percent increase over losses of $(29.86) per share
05-16 04:10